Centessa Pharmaceuticals plc
NASDAQ: CNTA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mario Alberto Accardi
- Employees
- 77
- Headquarters
- Altrincham, United Kingdom
- IPO year
- 2021
- Market cap
- $6.2B
- Website
- https://www.centessa.com
Loading CNTA…
Loading profile data…Frequently asked questions about CNTA
What does Centessa Pharmaceuticals plc (CNTA) do?
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III c...
Where does CNTA trade?
Centessa Pharmaceuticals plc (CNTA) trades on the NASDAQ Global Select.
What sector is CNTA in?
Centessa Pharmaceuticals plc (CNTA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Centessa Pharmaceuticals plc?
Mario Alberto Accardi is the chief executive officer of Centessa Pharmaceuticals plc (CNTA).
Where is Centessa Pharmaceuticals plc headquartered?
Centessa Pharmaceuticals plc is headquartered in United Kingdom.
Does CNTA pay a dividend?
Centessa Pharmaceuticals plc (CNTA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CNTA go public?
Centessa Pharmaceuticals plc (CNTA) completed its initial public offering in 2021.
Is CNTA an ADR?
Yes — CNTA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Centessa Pharmaceuticals plc reporting and dividends follow the underlying issuer.